Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18045018 | 1.00 | BTK (0.69) | BTKKCNH2 | |
| SCHEMBL16671655 | 0.83 | BTK (0.71) | BTKKCNH2 | |
| SCHEMBL16671299 | 0.83 | BTK (0.71) | BTKKCNH2 | |
| SCHEMBL16676778 | 0.83 | BTK (0.65) | BTKKCNH2 | |
| SCHEMBL18045003 | 0.83 | BTK (0.65) | BTKKCNH2 | |
| SCHEMBL16676657 | 0.82 | BTK (0.70) | BTKKCNH2 | |
| SCHEMBL18044927 | 0.82 | BTK (0.70) | BTKKCNH2 | |
| SCHEMBL16671205 | 0.81 | BTK (1.00) | BTKKCNH2 | |
| SCHEMBL16671266 | 0.81 | BTK (1.00) | BTKKCNH2 | |
| SCHEMBL16670391 | 0.81 | BTK (1.00) | BTKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| CN-105939998-B | Heteroaryl compound and application thereof as BTK inhibitor | 默克专利有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| CN-105939998-A | Heteroaryl compounds as btk inhibitors and uses thereof | 默克专利有限公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | BTK 1/4885KCNH2 2256/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | BTK 1/4885KCNH2 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.